1978
DOI: 10.1210/jcem-46-5-734
|View full text |Cite
|
Sign up to set email alerts
|

Detection and Properties of TSH-Binding Inhibitor Immunoglobulins in Patients with Graves’ Disease and Hashimoto’s Thyroiditis*

Abstract: TSH-binding inhibitor immunoglobulins (TBII) have been detected in patients with Graves' disease and Hashimoto's thyroiditis by using the radioreceptor assay of TSH. In untreated Graves' patients, TBII levels correlated well with thyroidal 99mTc uptake at 30 min and the grade of epithelial hyperplasia of thyroid follicles. There were many Graves' patients whose sera contained high TBII levels but no detectable bioassayable thyroid-stimulating activity (LATS), and in these patients, close correlation was observ… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

3
104
1
3

Year Published

1982
1982
2013
2013

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 292 publications
(111 citation statements)
references
References 21 publications
3
104
1
3
Order By: Relevance
“…In 1965, this substance called long-acting thyroid stimulator was characterized as being an antibody against a thyroid component (5). In 1978, this thyroid component was identified as the TSH receptor (RTSH) (6).…”
Section: Introductionmentioning
confidence: 99%
“…In 1965, this substance called long-acting thyroid stimulator was characterized as being an antibody against a thyroid component (5). In 1978, this thyroid component was identified as the TSH receptor (RTSH) (6).…”
Section: Introductionmentioning
confidence: 99%
“…GD patients without and with ophthalmopathy were 111 and 88, respectively. For anti-TSH receptor antibodies, TBII (TSH binding inhibitor immunoglobulin) activity (Rees Smith et al 1988;Endo et al 1978) was measured, because TBII activity was most frequently measured at the onset of GD as an anti-TSH receptor antibody. GD patients with potent ( ‡50%) and weak (<50%) TBII were 64 and 90, respectively.…”
Section: Clinical Manifestations Of Graves' Patientsmentioning
confidence: 99%
“…TSAb, after the interaction with the receptor, increase cAMP accumulation causing goiter and hyperthyroidism (2,3). In atrophic thyroiditis (AT), thyroid-stimulating blocking antibodies (TSHBAb) are TSH antagonists, inhibiting TSH binding or TSH-increased cAMP levels causing thyroid atrophy and hypothyroidism (2,(4)(5)(6). The different activities of TSAb and TSHBAb suggest they might interact with different epitopes on the TSHr (2).…”
Section: Introductionmentioning
confidence: 99%